IKEA Expands U.S. Manufacturing Amid Rising Tariffs and Supply Chain Strategy Shift 
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
Tesla Expands Affordable Model 3 Lineup in Europe to Boost EV Demand 
Michael Dell Pledges $6.25 Billion to Boost Children’s Investment Accounts Under Trump Initiative 
BOJ Governor Ueda Highlights Uncertainty Over Future Interest Rate Hikes 
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines 
Australia Moves Forward With Teen Social Media Ban as Platforms Begin Lockouts 
GM Issues Recall for 2026 Chevrolet Silverado Trucks Over Missing Owner Manuals 
Neuralink Expands Brain Implant Trials with 12 Global Patients 
Tabletop particle accelerator could transform medicine and materials science 
U.S. Experts to Reassess Newborn Hepatitis B Vaccination Guidelines Amid Growing Debate 
U.S. Reveals 2026 Medicare Star Ratings: Aetna, UnitedHealth Lead in Quality Scores 
Anthropic Reportedly Taps Wilson Sonsini as It Prepares for a Potential 2026 IPO 
Airline Loyalty Programs Face New Uncertainty as Visa–Mastercard Fee Settlement Evolves 
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options 
FDA Names Tracy Beth Høeg as Acting CDER Director After Richard Pazdur Announces Retirement 
Lost in space: MethaneSat failed just as NZ was to take over mission control – here’s what we need to know now 
South Korea’s Celltrion Inc. will jointly develop and work on the market release with Abpro Corp. of the US on a breast cancer treatment candidate ABP 10
Under the deal, Celltrion will receive US$10 million in milestone payments after successfully passing key stages of the development and approval cycle.
Celltrion, an Incheon-based biopharmaceutical company, will also be eligible to collect $1.75 billion from Abpro after ABP 102 generates sales following its market debut. Additionally, it has secured the rights for the candidate's international sales.
The Massachusetts-based Abpro is developing eight other cancer treatment candidates.
ABP 102 is a dual antibody treatment used to treat breast cancer that is HER2-positive.
